Loading organizations...
§ Private Profile · Wuhan, Hubei, China
Biotechnology company develops allogeneic cell therapies for Parkinson's disease and blindness, focused on chemical induction.
iRegene Therapeutics is a Chengdu, China-based biotechnology company developing chemically induced allogeneic cell therapies to reprogram cell fate and optimize cellular functions. The firm focuses on incurable conditions like Parkinson's disease and blindness, with its flagship product, NouvNeu001, receiving FDA Fast Track Designation on August 15, 2025, and a Special Exemption in March 2024. iRegene Therapeutics has secured multiple financing rounds, including a Series B+ round on September 4, 2025, with prior investment from Northern Light Venture Capital, Chuangjing Capital, and OneHealth Haihe Capital. Its proprietary platform generates high-purity, functional human cell types for next-generation treatments. Founded in 2017 by Dr. Jun Wei. Its business model centers on biotech R&D funded through venture capital investments, including multiple financing rounds.
iRegene Therapeutics has raised $42.1M across 1 funding round.
iRegene Therapeutics has raised $42.1M in total across 1 funding round.
iRegene Therapeutics has raised $42.1M across 1 funding round. Most recently, it raised $42.1M Series B in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 9, 2025 | $42.1M Series B | Chuangjing Capital, Northern Light Venture Capital, Onehealth Haihe Capital | — | Announced |
iRegene Therapeutics has raised $42.1M in total across 1 funding round.
iRegene Therapeutics's investors include Chuangjing Capital, Northern Light Venture Capital, OneHealth Haihe Capital.